Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, 10 Patent Applications Related to RNAi

Premium
(Editor’s Note: This week’s IP Update includes patent and patent applications previously published but not included in last week’s issue of RNAi News due to technical difficulties.)
 

Title: Compositions and Methods for siRNA Inhibition of Angiogenesis
 
Number: 7,345,027
 
Filed: June 8, 2006
 
Lead Inventor: Michael Tolentino, University of Pennsylvania (Opko Health)
 
The patent, its abstract states, claims “RNA interference using small interfering RNAs … specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR.
 
The abstract adds that “diseases which involved angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age-related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.”
 

 
Title: Therapeutic Uses of Inhibitors of RTP801L
 
Number: 20080064650
 
Filed: June 8, 2007
 
Lead Inventor: Elena Feinstein, Quark Pharmaceuticals
 
The invention “provides novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, respiratory conditions, and hearing disorders based upon inhibition of the RTP801L gene and/or protein.”
 
The patent application notes that the invention “relates to novel siRNA molecules” that inhibit RTP801L.
 

 
Title: Methods and Compositions Relating to Lipid Accumulation
 
Number: 20080064648
 
Filed: June 16, 2004 PCT Filed: June 16, 2004
 
Lead Inventor: Gary Ruvkun, Harvard Medical School
 
“In general, this invention relates to nucleic acid and amino acid sequences [including dsRNA] involved in lipid accumulation, screening methods for identifying genes that regulate lipid accumulation, and the use of these sequences as targets for the diagnosis, treatment, and prevention of obesity and obesity-related diseases,” the patent application’s abstract states.
 

 
Title: siRNA Targeting Cyclin-Dependent Kinase 11
 
Number: 20080064865
 
Filed: May 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDK11.”
 

 
Title: Short Interfering RNA Duplexes Targeting an IRES Sequence and Uses Therefore
 
Number: 20080066196
 
Filed: April 19, 2007
 
Inventor: Gene Lee, Wyeth
 
The invention claims “novel inhibitory polynucleotides directed against [internal ribosome entry sites] sequences,” the patent application’s abstract states. “The invention also provides genetically engineered expression vectors, host cells, transgenic animals, and transgenic plants comprising the novel inhibitory polynucleotides of the invention … [as well as] methods of using the inhibitory polynucleotides of the invention.”
 

 
Title: Phased Small RNAs
 
Number: 20080066206
 
Filed: Aug. 31, 2007
 
Lead Inventor: Edwards Allen, Monsanto
 
The invention “discloses recombinant DNA constructs encoding phased small RNAs useful in regulating expression of one or more genes of interest,” as well as transgenic plant cells, plants, and seeds containing a recombinant DNA construct of the invention.
 

 
Title: RNA Interference That Blocks Expression of Pro-Apoptotic Proteins Potentiates Immunity Induced by DNA and Transfected Dendritic Cell Vaccines
 
Number: 20080069840
 
Filed: July 3, 2007
 
Lead Inventor: Tzyy-Choou Wu, Johns Hopkins School of Medicine
 
The patent application, its abstract states, claims “an immunotherapeutic strategy … that combines antigen-encoding DNA vaccine compositions combined with siRNA directed to pro-apoptotic genes, primarily Bak and Bax, the products of which are known to lead to apoptotic death.
 
“Gene-gun delivery of siRNA specific for Bak and/or Bax to antigen-expressing DCs prolongs the lives of such DCs and lead to enhanced generation of antigen-specific CD8+ T cell-mediated immune responses in vivo,” the abstract notes. “Similarly, antigen-loaded DC's transfected with siRNA targeting Bak and/or Bax serve as improved immunogens and tumor immunotherapeutic agents.”
 

 
Title: Inhibition of Expression of a Target Gene
 
Number: 20080070305
 
Filed: Nov. 16, 2007
 
Lead Inventor: Ulrich Certa, Roche
 
The invention, the patent application’s abstract states, comprises “a process to inhibit the expression of a target gene in cells or tissues by infecting said cells or tissues with viral particles.”
Specifically, the application claims “a process to inhibit the expression of a target gene in cells or tissues comprising infection of said cells or tissues with viral particles containing single-stranded ribonucleic acid expressing a sense RNA strand and viral particles containing single-stranded ribonucleic acid [expressing an] antisense RNA strand, wherein the sense and antisense RNA strands comprises homologous nucleotide sequences to a portion of [a] target gene.”
 

 
Title: Conserved HBV and HCV Sequences Useful in Gene Silencing
 
Number: 20080070854
 
Filed: June 10, 2004 PCT Filed: June 10, 2004
 
Lead Inventor: Catherine Pachuk, Nucleonics
 
The patent application, claims “conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells,” according to its abstract. “These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.”
 

 
Title: siRNA Targeting Ubiquitin Ligases
 
Number: 20080071073
 
Filed: Oct. 25, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for ubiquitin ligases.”
 

 
Title: siRNA Targeting Proteasome 26S Subunit, Non-ATPase, 10
 
Number: 20080071075
 
Filed: June 8, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, “efficient sequence-specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PSMD10.”

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.